NCT03089138View on ClinicalTrials.gov

Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome

PHASE2UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Cold
Interventions
DRUG

Regan Tangjiang

The treatment duration is 3 consecutive days.

Sponsors
All Listed Sponsors
lead

Beijing Da-an Bio-technology Co., Ltd.

INDUSTRY